Literature DB >> 31031174

Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group.

Pietro Andreone1, Vito Di Marco2, Giovanni Battista Gaeta3, Stefano Fagiuoli4, Ranka Vukotic5, Antonio Craxì6.   

Abstract

Hepatitis C virus (HCV) remains a significant public health problem and is one of the major causes of chronic liver disease worldwide. In recent years many new tools to facilitate widespread HCV screening and new therapeutic options with excellent efficacy and tolerability profiles and cost lowering policies have become available. To fully utilise these new tools, the link between local and specialist centres for the management of HCV infection must be reinforced. In order to GAIN further insight into these aspects, with a particular focus on the Italian scenario, a group of experts met to discuss relevant aspects and open issues on chronic HCV. As a summary of that meeting, the following aspects are here overviewed: (i) global situation of HCV; (ii) screening, diagnosis and indications for the treatment of HCV; (iii) the Italian situation of HCV referrals; (iv) 'hard to reach' patients; (v) treatment of HCV with extrahepatic manifestations; (vi) treatment of patients with advanced cirrhosis. It is the intention of the expert panel to further promote widespread screening and eradication policies that should be accompanied by greater interaction, by attempting to involve all healthcare providers in an organised process to facilitate linkage to care of patients with HCV infections.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Eradication; Hepatitis C virus; Linkage to care

Mesh:

Substances:

Year:  2019        PMID: 31031174     DOI: 10.1016/j.dld.2019.03.033

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Intention to Screen for Hepatitis C Among University Students: Influence of Different Communicative Scenarios.

Authors:  Pierluigi Diotaiuti; Stefania Mancone; Lavinia Falese; Maria Ferrara; Fernando Bellizzi; Giuseppe Valente; Stefano Corrado; Francesco Misiti
Journal:  Front Psychiatry       Date:  2022-05-11       Impact factor: 5.435

2.  Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients.

Authors:  Olivera Djuric; Marco Massari; Marta Ottone; Giorgia Collini; Pamela Mancuso; Massimo Vicentini; Antonio Nicolaci; Angela Zannini; Alessandro Zerbini; Valeria Manicardi; Loreta A Kondili; Paolo Giorgi Rossi
Journal:  Infect Agent Cancer       Date:  2021-01-19       Impact factor: 2.965

3.  Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.

Authors:  Massimo Andreoni; Giovanni Di Perri; Marcello Persico; Andrea Marcellusi; Olivier Ethgen; Yuri Sanchez Gonzalez; Mark Bondin; Zhenzhen Zhang; Antonella De Michina; Rocco Cosimo Damiano Merolla; Antonio Craxì
Journal:  Infect Dis Ther       Date:  2021-03-03

4.  Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy.

Authors:  Pierluca Piselli; Diego Serraino; Mario Fusco; Enrico Girardi; Angelo Pirozzi; Federica Toffolutti; Claudia Cimaglia; Martina Taborelli
Journal:  BMC Infect Dis       Date:  2021-07-08       Impact factor: 3.090

5.  Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.

Authors:  Rodolfo Castro; Hugo Perazzo; Letícia Artilles Mello Mendonça de Araujo; Isabella Gonçalves Gutierres; Beatriz Grinsztejn; Valdiléa G Veloso
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.